Sunovion Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co. Ltd. and its U.S. subsidiary, Sunovion Pharmaceuticals Inc. of Marlborough filed patent infringement lawsuits Wednesday related to its antipsychotic drug Lutuda.

Sunovion Pharmaceuticals Inc. of Marlborough has submitted a supplemental new drug application to the Food and Drug Administration. The application seeks approval for the use of Aptiom for monotherapy treatment of partial-onset seizures in patients with epilepsy.

Marlborough-based Sunovion Pharmaceuticals said it has agreed to sell rights to its drug Xopenex Inhalation Solution (IS), used in the treatment of obstructive airway disease such as asthma.

The U.S. Food and Drug Administration (FDA) is warning users of Lunesta, made by Marlborough's Sunovion Pharmaceuticals, that the insomnia drug can cause next-day impairment of driving and other activities requiring alertness.

A new drug from Sunovion Pharmaceuticals aimed at reducing seizures associated with epilepsy is now available by prescription in pharmacies across the United States.

Sunovion Pharmaceuticals reported positive late-stage test results for a new drug as both an add-on and standalone treatment for seizures associated with epilepsy.

The U.S. Food and Drug Administration has approved a new drug made by Sunovion Pharmaceuticals to reduce seizures associated with epilepsy.

The U.S. Food and Drug Administration has asked Marlborough-based Sunovion Pharmaceuticals Inc. to stop distributing promotional brochures for respiratory drug Brovana that it considers deceptive, according to a letter released Tuesday.

A federal appellate court ruled last week that a planned generic sleep aid would infringe on Sunovion Pharmaceuticals Inc. patent for its Lunesta drug, rerversing a lower-court ruling against the Marlborough firm.